Experimental drug retatrutide cuts knee pain and weight in phase III trials
सिर्फ तथ्य

Experimental drug retatrutide cuts knee pain and weight in phase III trials

सारांश

Phase III trials of the injectable drug retatrutide showed participants lost about 25% of body weight and reported significant reductions in knee osteoarthritis pain.

Two Northwestern University-led phase III trials involving more than 1,000 overweight or obese adults with painful knee osteoarthritis found that participants receiving the highest dose of retatrutide lost roughly one-quarter of their body weight on average. About two-thirds of those treated experienced at least a 50% reduction in knee pain, compared with 38% of placebo recipients. The studies also reported improvements in blood pressure, lipid levels and systemic inflammation.

The results, published in the New England Journal of Medicine, were presented at the American College of Rheumatology meeting. Corresponding author Dr. Thomas Schnitzer said the findings suggest that substantial weight loss from the treatment can lead to meaningful pain reduction because less load is placed on the knees.

Retatrutide, a once-weekly injectable developed by Eli Lilly, activates three hormone receptors and achieved 20%-25% weight loss in participants, exceeding the 10%-20% typical of existing GLP-1 drugs such as semaglutide or tirzepatide. Schnitzer noted that many participants lost considerable weight, with some losing up to 100 pounds (45 kg).

While diet, exercise and lifestyle changes remain the first-line approach, the drug could offer an alternative for patients who cannot achieve sufficient weight loss and continue to experience disabling knee pain, pending FDA approval. Researchers highlighted unanswered questions, including whether retatrutide can slow osteoarthritis progression enough to reduce the need for joint replacement and whether it is effective in non-overweight patients.

"The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you're going to get a meaningful reduction in your knee pain," said Dr. Schnitzer.

"Participants had remarkable responses. Many of the people in this study lost considerable amounts of weight, with a few losing up to 100 pounds (45 kilograms) or more," he added.

The trials excluded individuals awaiting knee replacement, and further research is needed to clarify the drug’s impact on disease progression and its anti-inflammatory mechanisms.

स्रोत

Medical Xpress

पहली बार यहां रिपोर्ट किया गया

पढ़ते रहें — निःशुल्क

समाचार फ़ॉलो करने के लिए मुफ़्त खाता बनाएँ। कार्ड की आवश्यकता नहीं।